Relapsed small cell lung cancer (SCLC) patients have limited treatment options and poor outcomes. NGR-hTNF is a vascular-targeting agent, which increases intratumoral chemotherapy penetration and T-lymphocyte infiltration.

NGR-hTNF and Doxorubicin as Second-Line Treatment of Patients with Small Cell Lung Cancer

Novello, S;Capelletto, Enrica;
2018-01-01

Abstract

Relapsed small cell lung cancer (SCLC) patients have limited treatment options and poor outcomes. NGR-hTNF is a vascular-targeting agent, which increases intratumoral chemotherapy penetration and T-lymphocyte infiltration.
2018
///
///
Gregorc, Vanesa; Cavina, Raffaele; Novello, S; Grossi, Francesco; Lazzari, Chiara; Capelletto, Enrica; Genova, Carlo; Salini, Giulia; Lambiase, Antonio; Santoro, Armando
File in questo prodotto:
File Dimensione Formato  
NGR-hTNF and doxorubicin as second line treatment of patients with small cell lung cancer_.pdf

Accesso riservato

Tipo di file: PDF EDITORIALE
Dimensione 256.85 kB
Formato Adobe PDF
256.85 kB Adobe PDF   Visualizza/Apri   Richiedi una copia

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/2318/1675981
Citazioni
  • ???jsp.display-item.citation.pmc??? 14
  • Scopus 19
  • ???jsp.display-item.citation.isi??? 19
social impact